SCHEMBL5469832

SCHEMBL5469832

O=C(Nc1ccc(O)cc1)c1c[c]ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.60
▸ DEGS1 O15121 2/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ TP53 P04637 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ NQO2 P16083 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ P2RX1 P51575 1/20 0.45
▸ SNCA P37840 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462663 0.86 MEN1 (0.47) LMNAMEN1KMT2ATP53HTT
SCHEMBL5462330 0.84 PNLIP (0.62) LMNAMEN1KMT2ATP53NPC1
SCHEMBL5468300 0.84 SNCA (0.56) MEN1KMT2ANPC1RAB9AP2RX1
SCHEMBL5463771 0.82 RAB9A (0.51) LMNAMEN1KMT2ATP53HTT
SCHEMBL5464092 0.82 TOP1 (0.46) LMNAMEN1KMT2ATP53HTT
SCHEMBL5463705 0.81 SRC (0.55) LMNAMEN1KMT2ATP53HTT
SCHEMBL5455155 0.80 MEN1 (0.40) LMNAMEN1KMT2ATP53HTT
SCHEMBL5463888 0.80 PTGS1 (0.56) LMNAMEN1KMT2AKDM4ENPC1
SCHEMBL5457651 0.78 KCNQ3 (0.52) RAB9ASMN1; SMN2
SCHEMBL5468424 0.77 NPC1 (0.56) LMNAMEN1KMT2ATP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 LMNA 1135/4885DEGS1 1903/4885MEN1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback